日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Identification of Hidden Cachexia Subgroup in PD-L1-High NSCLC: Comparative Analysis of the AWGC vs. Fearon Criteria

PD-L1高表达非小细胞肺癌中隐匿性恶病质亚组的识别:AWGC标准与Fearon标准的比较分析

Nishioka, Naoya; Kawachi, Hayato; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Ogawa, Takeo; Iwasaku, Masahiro; Tokuda, Shinsaku; Kijima, Takashi; Takayama, Koichi

AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers

AXL-SHC1信号轴介导HER2异常肺癌和胃癌对HER2靶向酪氨酸激酶抑制剂的适应性耐药

Ishida, Masaki; Yamada, Tadaaki; Katayama, Yuki; Kawachi, Hayato; Sawada, Ryo; Nakamura, Ryota; Hirai, Soichi; Matsui, Yohei; Morimoto, Kenji; Onoi, Keisuke; Nakamura-Sasada, Aosa; Horinaka, Mano; Sakai, Toshiyuki; Sakakida, Tomoki; Doi, Toshifumi; Yasumoto, Kazuo; Goto, Yasuhiro; Furuya, Naoki; Taniguchi, Hirokazu; Ogino, Hirokazu; Takayuki, Nakano; Chihara, Yusuke; Fukuda, Koji; Taniguchi, Hiroaki; Uehara, Hisanori; Yano, Seiji; Tokuda, Shinsaku; Takayama, Koichi

Impact of vulnerability on concurrent chemoradiotherapy outcomes in patients with locally advanced non-small cell lung cancer using an integrated clinical trial database

利用综合临床试验数据库分析脆弱性对局部晚期非小细胞肺癌患者同步放化疗疗效的影响

Morimoto, Kenji; Yamada, Tadaaki; Nishioka, Naoya; Yamamoto, Nobuyuki; Niho, Seiji; Okamoto, Isamu; Hotta, Katsuyuki; Okamoto, Hiroaki; Sugawara, Shunichi; Shimokawa, Toshio; Ozawa, Yuichi; Oizumi, Satoshi; Takayama, Koichi

Hydrostatic pressure from basal side promotes cancer proliferation, enhances migration, and alters cell polarity: A model of the effects of interstitial fluid pressure in tumor microenvironment

基底侧静水压力促进癌细胞增殖、增强癌细胞迁移并改变细胞极性:肿瘤微环境中间质液压力效应的模型

Onoi, Keisuke; Nakamura-Sasada, Aosa; Tokuda, Shinsaku; Fukui, Mototaka; Katayama, Yuki; Kawachi, Hayato; Nishioka, Naoya; Iwasaku, Masahiro; Sakai, Toshiyuki; Furuya, Tatsuo; Ishihara, Shunta; Okada, Satoru; Inoue, Masayoshi; Yamada, Tadaaki; Takayama, Koichi

Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy

癌症恶病质对PD-L1肿瘤比例评分≥50%的非小细胞肺癌患者接受帕博利珠单抗单药治疗与免疫检查点抑制剂联合化疗治疗预后的临床影响

Kawachi, Hayato; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Kijima, Takashi; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Katayama, Yuki; Nishioka, Naoya; Morimoto, Kenji; Iwasaku, Masahiro; Tokuda, Shinsaku; Shimose, Takayuki; Takayama, Koichi

Prognostic factors in patients with interstitial lung disease treated with nintedanib: a multicenter retrospective study in Japan

日本一项多中心回顾性研究探讨了接受尼达尼布治疗的间质性肺病患者的预后因素。

Goda, Shiho; Yamada, Tadaaki; Goto, Yasuhiro; Uda, Sayaka; Nakao, Akira; Shiotsu, Shinsuke; Kukida, Yuji; Tanimura, Keiko; Miyamoto, Akifumi; Imasato, Yuki; Okada, Asuka; Hasegawa, Isao; Date, Koji; Matsui, Yohei; Morito, Shoki; Inoguchi, Noeru; Osugi, Shuji; Kawachi, Hayato; Nishioka, Naoya; Iwasaku, Masahiro; Tokuda, Shinsaku; Handa, Tomohiro; Takayama, Koichi

Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non-Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study

TTF-1表达对PD-L1表达水平为1%至49%的非小细胞肺癌患者接受化疗与化疗免疫治疗预后预测的影响:一项多中心回顾性研究

Nishioka, Naoya; Hata, Tae; Yamada, Tadaaki; Goto, Yasuhiro; Amano, Akihiko; Negi, Yoshiki; Watanabe, Satoshi; Furuya, Naoki; Oba, Tomohiro; Ikoma, Tatsuki; Nakao, Akira; Tanimura, Keiko; Taniguchi, Hirokazu; Yoshimura, Akihiro; Fukui, Tomoya; Murata, Daiki; Kaira, Kyoichi; Shiotsu, Shinsuke; Hibino, Makoto; Okada, Asuka; Chihara, Yusuke; Kawachi, Hayato; Kijima, Takashi; Takayama, Koichi

Impact of mutant protein expression on clinical outcomes in patients with EGFR L858R-mutated non-small cell lung cancer

突变蛋白表达对EGFR L858R突变型非小细胞肺癌患者临床结局的影响

Nakamura, Ryota; Yamada, Tadaaki; Morimoto, Kenji; Yoshimura, Akihiro; Shiotsu, Shinsuke; Motono, Nozomu; Uramoto, Hidetaka; Imabayashi, Tatsuya; Takemura, Yoshizumi; Katayama, Yuki; Nishioka, Naoya; Iwasaku, Masahiro; Tokuda, Shinsaku; Okada, Satoru; Shimomura, Masanori; Inoue, Masayoshi; Tanaka, Noriyuki; Miyagawa-Hayashino, Aya; Takayama, Koichi

Utility of serum CYFRA 21-1 as a prognostic biomarker in ALK-positive non-small cell lung cancer treated with ALK-TKIs: a retrospective cohort study

血清CYFRA 21-1作为ALK阳性非小细胞肺癌患者接受ALK-TKI治疗的预后生物标志物的应用价值:一项回顾性队列研究

Sawada, Ryo; Yamada, Tadaaki; Goto, Yasuhiro; Negi, Yoshiki; Nakao, Akira; Yoshimura, Akihiro; Furuya, Naoki; Oba, Tomohiro; Hibino, Makoto; Nakatani, Haruka; Taniguchi, Hirokazu; Ohtsubo, Aya; Watanabe, Satoshi; Yamada, Takahiro; Chihara, Yusuke; Kijima, Takashi; Takayama, Koichi

Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy

基于炎症情况选择最佳免疫疗法治疗PD-L1 ≥50%基因突变阴性IV期非小细胞肺癌:帕博利珠单抗单药治疗与联合化疗免疫疗法

Kunimatsu, Yusuke; Nishioka, Naoya; Yamada, Tadaaki; Kawachi, Hayato; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Ishida, Masaki; Kijima, Takashi; Takayama, Koichi